Pastore F et al (Oct. 2014) The NPM1 mutation type has no impact on survival in cytogenetically normal AML. PLoS ONE 9(10). https://doi.org/10.1371/journal.pone.0109759

Brodská B, Kráèmarová M, Holoubek A, Kuželová K (2017) Localization of AML-related nucleophosmin mutant depends on its subtype and is highly affected by its interaction with wild-type NPM. PLoS One 12(4). https://doi.org/10.1371/journal.pone.0175175

Papaemmanuil E et al (2016) Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med 374(23):2209–2221. https://doi.org/10.1056/nejmoa1516192

Oñate G et al (2022) Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Blood Adv 6(3):882–890. https://doi.org/10.1182/bloodadvances.2020004136

Ferrari B, Peyvandi F (2020) How I treat thrombotic thrombocytopenic purpura in pregnancy. Blood 136(19):2125–2132. https://doi.org/10.1182/BLOOD.2019000962

Jahn N et al (2022) Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial. Leukemia 36(9):2218–2227. https://doi.org/10.1038/s41375-022-01650-w

Abbas HA et al (2019) NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia. Wiley-Liss Inc. https://doi.org/10.1002/ajh.25454

Othman J et al (2023) FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML. Leukemia 37(10):2066–2072. https://doi.org/10.1038/s41375-023-01994-x

Article  CAS  Google Scholar 

Angenendt L et al (2023) Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification. Blood 141(4):433–435. https://doi.org/10.1182/blood.2022018582

Kapp-Schwoerer S et al (2020) Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09–09 trial [Online]. Available: http://ashpublications.org/blood/article-pdf/136/26/3041/1795435/bloodbld2020005998.pdf

Angenendt L et al (2019) Chromosomal abnormalities and prognosis in NPM1-Mutated Acute myeloid leukemia: a pooled analysis of Individual Patient Data from Nine International Cohorts. J Clin Oncol 37. https://doi.org/10.1200/JCO.19

Khoury JD et al (2022) The 5th edition of the World Health Organization Classification of Hematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Springer Nature. https://doi.org/10.1038/s41375-022-01613-1

Swanson HD et al (2020) Predicting success of desensitization after pegaspargase allergy. Am Soc Hematol. https://doi.org/10.1182/blood.2019003407

Article  Google Scholar 

Ostronoff F et al (2015) Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: A SWOG and UK national cancer research institute/medical research council report. J Clin Oncol 33(10):1157–1164. https://doi.org/10.1200/JCO.2014.58.0571

Chan O et al (2024) Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML. Blood Adv 8(5):1075–1083. https://doi.org/10.1182/bloodadvances.2023011173

Thiede C et al (2006) Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). https://doi.org/10.1182/blood-2005-08

de Jonge HJM et al (2011) Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: Relevance of mutated NPM1 and FLT3-ITD. Haematologica 96(9):1311–1317. https://doi.org/10.3324/haematol.2011.040592

Ivey A et al (2016) Assessment of minimal residual disease in Standard-Risk AML. N Engl J Med 374(5):422–433. https://doi.org/10.1056/nejmoa1507471

Russell NH et al (Apr. 2024) Fludarabine, Cytarabine, Granulocyte colony-stimulating factor, and Idarubicin with Gemtuzumab Ozogamicin improves event-free survival in younger patients with newly diagnosed AML and overall survival in patients with NPM1 and FLT3 mutations. in Journal of Clinical Oncology. Lippincott Williams and Wilkins, pp 1158–1168. doi: https://doi.org/10.1200/JCO.23.00943.

Fournier E et al (2020) Brief Report MYELOID NEOPLASIA Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia [Online]. Available: http://ashpublications.org/blood/article-pdf/135/8/542/1716659/bloodbld2019003471.pdf

Dillon R et al United Kingdom; 15 Beatson Cancer Centre, 2020. [Online]. Available: http://www.isrctn.com/ISRCTN55675535

Grimwade D et al (2010) Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116(3):354–365. https://doi.org/10.1182/blood-2009-11-254441

Cheson BD et al (2003) Revised Recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21(24):4642–4649. https://doi.org/10.1200/JCO.2003.04.036

Van Buuren S (2011) Groothuis-Oudshoorn K Journal of Statistical Software mice: Multivariate Imputation by Chained Equations in R. [Online]. Available: http://www.jstatsoft.org/

Augustin T (2004) Bradley-Terry-Luce models to incorporate within-pair order effects: Representation and uniqueness theorems. Br J Math Stat Psychol 57(2):281–294. https://doi.org/10.1348/0007110042307195

Balsat M et al (2017) Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: A study by the acute leukemia French association group. J Clin Oncol 35(2):185–193. https://doi.org/10.1200/JCO.2016.67.1875

Knapper S et al (2017) A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. Blood 129(9):1143–1154. https://doi.org/10.1182/blood-2016-07

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gale RE et al (2008) The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. https://doi.org/10.1182/blood-2007-08

Al-Sawaf O et al (2020) High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia. Am J Hematol. https://doi.org/10.1182/BLOOD.2019003451

Article  Google Scholar 

Virappane P et al (2008) Mutation of the Wilms’ tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: The United Kingdom medical research council adult leukaemia working party. J Clin Oncol. 26(33):5429–5435. https://doi.org/10.1200/JCO.2008.16.0333

Becker H et al (2010) Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: A Cancer and leukemia group B study. Blood 116(5):788–792. https://doi.org/10.1182/blood-2010-01-262543

Renneville A et al (2009) Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: A study from the Acute Leukemia French Association. Cancer 115(16):3719–3727. https://doi.org/10.1002/cncr.24442

Molecular subtypes Of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia total cohort (n = 660) type A (n = 458) type B (n = 72) type D (n = 51) remaining (n = 79) n % n % n % n % n %

Heiblig M et al (2019) Impact of NPM1 mutation subtypes on treatment outcome in AML: The Lyon-University Hospital experience. Elsevier Ltd. https://doi.org/10.1016/j.leukres.2018.11.016

Park BG et al (2012) Clinical implications of non-A-type NPM1 and FLT3 mutations in patients with normal karyotype acute myeloid leukemia. Acta Haematol 127(2):63–71. https://doi.org/10.1159/000331509

Paschka P et al (2008) Wilms’ tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study. J Clin Oncol. 26(28):4595–4602. https://doi.org/10.1200/JCO.2007.15.2058

Wang Y et al (Jan. 2023) The impact of mutation of Myelodysplasia-related genes in De Novo Acute myeloid leukemia carrying NPM1 mutation †. Cancers (Basel) 15(1). https://doi.org/10.3390/cancers15010198

Borrow J, Dyer SA, Akiki S, Griffiths MJ (2019) Molecular roulette: nucleophosmin mutations in AML are orchestrated through N-nucleotide addition by TdT, [Online]. Available: http://ashpublications.org/blood/article-pdf/134/25/2291/1549274/bloodbld2019001240.pdf